Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.A study conducted by the Pirbright Institute, in alliance with the University of Oxford, has demonstrated that two doses of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine boost antibody response in pigs, compared to a single dose.
ChAdOx1 nCoV-19 is a chimpanzee adenovirus vaccine vector comprising the SARS-CoV-2 spike protein. It has been developed at Oxford University’s Jenner Institute and licensed to AstraZeneca.
Phase 1 clinical trials of the single-dose vaccine are underway after preclinical research showed that the product could protect macaques against lung disease following a single immunisation.